FREE CONSULTATION
INTERNATIONAL PATIENT PROGRAM

SynerTri Immunotherapy:
The Evolution of Precision Immuno-Oncology

Decades of Immunotherapy Leadership.
Now Personalized to You.

As the first medical institution in the world to introduce WT1 dendritic cell vaccine therapy into clinical practice, Precision Clinic Group has built one of the world's leading clinical platforms in dendritic cell vaccine therapy. Today, we advance this legacy through SynerTri Immunotherapy—our integrated precision strategy for patients with advanced cancer.

What began as a breakthrough in dendritic cell vaccine technology has evolved into a comprehensive precision platform tailored to each patient's unique tumor biology. We do not simply activate the immune system—we design a strategic treatment environment in which anti-cancer immunity can function more effectively within the body.

Featured in the WSJ Next Era Leaders article: "Taking Personalized Oncology to the Wider World."

PROVEN RESULTS

6,500+

PATIENTS TREATED

One of the world's leading clinical records in dendritic cell vaccine therapy.

東大・阪大・北大

ACADEMIC HERITAGE

Built on technology developed at IMSUT, The University of Tokyo, and further developed through the WT1 platform pioneered at Osaka University and Hokkaido University.

World First

GLOBAL LEADERSHIP

The first medical institution to launch WT1 dendritic cell vaccine therapy worldwide.

A LEGACY OF INNOVATION

The Foundation of WT1 Dendritic Cell Therapy

Our clinical platform is rooted in advanced dendritic cell culture technology developed at The Institute of Medical Science, The University of Tokyo. By integrating the WT1 platform pioneered at Osaka University and Hokkaido University, we enabled the first global clinical application of WT1 dendritic cell vaccine therapy.

Why Experience Matters

Precision Clinic Group does not simply offer another immunotherapy program. We represent the continuation of a decades-long clinical and scientific evolution. With over 6,500 treated cases, our experience places us among the world's leading clinical groups in this field, underpinning a treatment platform shaped by decades of rigorous development and patient-centered care.

BEYOND WT1

Toward Individualized Precision Immuno-Oncology

Our platform has evolved beyond shared antigens alone. While WT1 remains a cornerstone, our strategy now incorporates Tumor-Associated Antigens (TAAs), Neoantigens, and autologous tumor tissue-derived antigens, depending on the specific biology of each patient's cancer.

The Shift to Neoantigen-Guided Therapy

Using each patient's unique genomic information, we identify specific neoantigen targets and design custom neoantigen-based dendritic cell vaccines when appropriate. This allows us to move from generalized antigen targeting toward a truly individualized precision immunotherapy platform.

WHAT IS SYNERTRI IMMUNOTHERAPY?

An Integrated Precision Strategy

SynerTri Immunotherapy is our original integrated cancer treatment strategy—a coordinated therapeutic design built around three key functions of anti-cancer immune activation.

COMPONENT ROLE MECHANISM
The Accelerator
01
 Dendritic Cell Vaccine Therapy Trains the immune system to recognize and attack cancer-specific targets, including WT1, TAAs, neoantigens, and autologous tumor tissue-derived antigens.
The Brake Release
02
 Immune Checkpoint Inhibitors Releases immune suppression pathways—such as PD-1, PD-L1, and CTLA-4—that tumors use to evade the immune system.
The Switch
03
 Local Tumor-Directed Therapy Uses radiation therapy, particle therapy, BNCT, or cryotherapy to generate the biological signals needed to awaken anti-cancer immunity.

SynerTri is not a single drug or a single procedure. It is a strategic, three-component platform designed to ensure that anti-cancer immunity functions effectively within the tumor microenvironment.

BUILT FOR PRECISION

Data-Driven Design

We believe cancer treatment must be designed around the molecular and immunological characteristics of each patient's tumor. By integrating genomic information with immunotherapy and local treatment, we move beyond general immune activation toward a strategy that is specific to the biology of the individual cancer.

WHAT IS SYNERTRI IMMUNOTHERAPY?

Practical Flow & Planning

Our process is designed for precision at every step.

01

Consultation & Planning

Tailoring the strategy to your unique tumor profile.

02

Apheresis

Collecting immune cells from your blood for vaccine production.

03

Manufacturing & Storage

Preparing your personalized dendritic cell vaccine.

04

Administration

Once every 1–3 weeks. Initial course: 7 sessions over approx. 4 months.

※

Neoantigen Note

For neoantigen-based vaccines, genomic analysis requires
2–3 months before administration.

FROM PIONEER TO PLATFORM

Precision Clinic Group pioneered WT1 dendritic cell vaccine therapy.

Today, that legacy has evolved into SynerTri Immunotherapy.

This history shapes our vision: from WT1 clinical leadership to a broader precision platform incorporating neoantigen-guided design and integrated immune strategies.

FOR INTERNATIONAL PATIENTS

We Welcome Patients from Around the World

Precision Clinic Group offers dedicated support for overseas patients, including second-opinion consultations to discuss treatment options, feasibility, timing, and customized planning. To learn more about SynerTri Immunotherapy and discuss whether this approach may be appropriate for your case, please contact our international team.

▶ REQUEST AN INTERNATIONAL CONSULTATION

SUGGESTED FAQ

Frequently Asked Questions

What is SynerTri Immunotherapy?

An integrated three-component strategy combining dendritic cell vaccine therapy, immune checkpoint inhibitors, and local tumor-directed therapy.

How does it differ from standard vaccine therapy?

It coordinates the vaccine with other treatments to ensure the immune system can strike the tumor effectively.

Is WT1 still used?

Yes. WT1 remains a core component and a key antigen within the SynerTri framework.

Do you offer neoantigen-based vaccines?

Yes. Custom-designed neoantigen approaches are utilized based on detailed genomic analysis.

What is the timeframe for international patients?

Preparation varies; for neoantigen-based vaccines, analysis and manufacturing typically take 2–3 months.